Aaron Miller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Aaron Miller has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Stein
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope
1 shared publication - Bijender Kumar
City of Hope
1 shared publication - Daniel A. Vallera
University of Minnesota Masonic Cancer Center, Section of Molecular Cancer Therapeutics, Therapeutic Radiology-Radiation Oncology, University of Minnesota, Minneapolis, MN 55423, USA
1 shared publication - Darren M. Zuro
City of Hope
1 shared publication - David Colcher
Department of Immunology and Theranostics, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA
1 shared publication - Indu Nair
City of Hope
1 shared publication
Latest Publications
- Open Access
AML ImmunoPET: 64 Cu-DOTA-anti-CD33 PET-CT imaging of AML in Xenograft mouse model
Purpose: Acute myeloid leukemia (AML) is a highly aggressive form of leukemia that results in poor survival outcomes. Currently, diagnosis and prognosis are based on invasive single-point bone marrow biopsies (iliac crest). There is currently no AML-specific non-invasive imaging method to assess disease in the whole body, including in extramedullary organs, representing an unmet clinical need. About 85-90% of human myeloid leukemia cells express CD33 (an accepted biomarker for AML) cell surface receptors, highlighting CD33 as an ideal candidate for AML immunoPET. Experimental Design: In this study, we evaluated if 64 Cu-DOTA-anti-CD33 murine monoclonal antibody (mAb) can be used for ImmunoPET-CT imaging of AML in preclinical model. For translational purpose, a humanized anti-CD33 antibody was produced, and after confirming its anti-CD33 PET-CT imaging ability we further explored its therapeutic potential. Results: 64 Cu-DOTA-anti-CD33 based PET-CT imaging detected CD33 + AML in mice with high sensitivity (95.65%) and specificity (100%). In the entire skeletal system, CD33 + PET activity was significantly high in the bones of AML bearing mice over non-leukemic control mice; femur (p+ PET activity prevelant in epiphysis/diaphysis of the bones, indicating spatial heterogeneity. Anti-CD33 therapy using newly developed humanized anti-CD33 mAb as an ADC (p=0.02) and 225 Ac-anti-CD33-RIT (p64 Cu-DOTA-anti-CD33), a CD33 PET-CT imaging modality was developed that detected AML with high sensitivity and specificity. The approach also indicated spatial heterogeneity in leukemic disease, dependent on disease burden, which warrants caution in analyzing results from single point bone marrow biopsies. Therefore, this imaging modality can be used to non-invasively detect AML in humans and also monitor treatment response, an unmet clinical need.
Open AccessAML ImmunoPET: 64 Cu-DOTA-anti-CD33 PET-CT imaging of AML in Xenograft mouse model
Purpose: Acute myeloid leukemia (AML) is a highly aggressive form of leukemia that results in poor survival outcomes. Currently, diagnosis and prognosis are based on invasive single-point bone marrow biopsies (iliac crest). There is currently no AML-specific non-invasive imaging method to assess disease in the whole body, including in extramedullary organs, representing an unmet clinical need. About 85-90% of human myeloid leukemia cells express CD33 (an accepted biomarker for AML) cell surface receptors, highlighting CD33 as an ideal candidate for AML immunoPET. Experimental Design: In this study, we evaluated if 64 Cu-DOTA-anti-CD33 murine monoclonal antibody (mAb) can be used for ImmunoPET-CT imaging of AML in preclinical model. For translational purpose, a humanized anti-CD33 antibody was produced, and after confirming its anti-CD33 PET-CT imaging ability we further explored its therapeutic potential. Results: 64 Cu-DOTA-anti-CD33 based PET-CT imaging detected CD33 + AML in mice with high sensitivity (95.65%) and specificity (100%). In the entire skeletal system, CD33 + PET activity was significantly high in the bones of AML bearing mice over non-leukemic control mice; femur (p+ PET activity prevelant in epiphysis/diaphysis of the bones, indicating spatial heterogeneity. Anti-CD33 therapy using newly developed humanized anti-CD33 mAb as an ADC (p=0.02) and 225 Ac-anti-CD33-RIT (p64 Cu-DOTA-anti-CD33), a CD33 PET-CT imaging modality was developed that detected AML with high sensitivity and specificity. The approach also indicated spatial heterogeneity in leukemic disease, dependent on disease burden, which warrants caution in analyzing results from single point bone marrow biopsies. Therefore, this imaging modality can be used to non-invasively detect AML in humans and also monitor treatment response, an unmet clinical need.